Valproate sodium contraindications

Valproate sodium
Depacon® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Valproate sodium
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Contraindications

Depacon should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].

Depacon is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].

Depacon is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].

Depacon is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].

References

Adapted from the FDA Package Insert.